Results 61 to 70 of about 25,780 (241)

Augmenting tumor sensitivity to topotecan by transient hypoxia

, 2005
We examined how the effect of topotecan is modulated by transient hypoxia in three different tumor lines, Lewis lung carcinoma (LLC), U87 human glioblastoma and DMS273 human small cell lung cancer.
Lund, Eva L., Hansen, Lasse T., Kristjansen, Paul E.G.   +2 more
core   +1 more source

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Future Oncology, 2019
Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment.
A. Farago, B. Drapkin, Jose Antonio Lopez-Vilarino de Ramos, C. Galmarini, R. Núñez, C. Kahatt, L. Paz-Ares   +6 more
semanticscholar   +1 more source

Smart mesoporous silica nanoparticles for precision cancer therapy: Tumor targeting and stimuli‐responsive controlled release

Smart Molecules, EarlyView.
Smart mesoporous silica nanoparticles integrate tunable pore structures, molecular gates, targeting ligands, and stimuli‐responsive components to achieve controlled drug release for precision cancer therapy. This review highlights design principles, therapeutic applications, and future directions in immunotherapy, biodegradability, biosafety, and ...
Majdi Al‐Amili, Lei Lei, Zhu Jin
wiley   +1 more source

IVT topotecan prolongs survival of mice with leptomeningeal D425 medulloblastoma compared to bolus IP topotecan.

, 2019
Kaplan-Meier survival curves of mouse groups are shown. (A) comparison of all groups. (B) Daily IP topotecan versus daily IP saline control. (C) Daily IP topotecan, daily IVT topotecan, or continuous IVT topotecan infusion via pump.
Ellis F. Meng (6175520), Min Y. Mahdi (2838335), Tuan Q. Hoang (6175517), Rex A. Moats (370209), Anat Erdreich-Epstein (312560), Debra Hawes (20923), Hung C. Tran (6175511), Jonathan L. Finlay (6175514), Gregory M. Shackleford (2838326)   +8 more
core   +1 more source

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan

Parasites & Vectors, 2021
Background The evolution of drug resistance is one of the biggest challenges in leishmaniasis and has prompted the need for new antileishmanial drugs.
Chloé Rosa-Teijeiro, Victoria Wagner, Audrey Corbeil, Ilda d’Annessa, Philippe Leprohon, Rubens L. do Monte-Neto, Christopher Fernandez-Prada   +6 more
doaj   +1 more source

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer

British Journal of Cancer, 2020
This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. Patients with platinum-sensitive recurrent or platinum-resistant recurrent ovarian cancer (PRROC) were randomised 1:1 to receive belotecan 0.5 ...
H. Kim, S. Park, Chan-Yong Park, Y. T. Kim, Beob-Jong Kim, Yong J. Song, Byoung-Gie Kim, Y. B. Kim, C. Cho, Jong-Hyeok Kim, Yong-Sang Song   +10 more
semanticscholar   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Mechanism-based models for topotecan-induced neutropenia

, 2004
OBJECTIVE: A semiphysiologic pharmacokinetic-pharmacodynamic model was applied to describe topotecan-induced neutropenia, to quantify interindividual and intraindividual pharmacodynamic variability, and to study the effect of covariates on the model ...
Chatelut, Etienne, Léger, Frédéric, Mathijssen, Ron H J; id_orcid, Goffinet, Marine, Bugat, Roland, Verweij, Jaap, Sparreboom, Alex, Loos, Walter J   +7 more
core   +1 more source

An inhibitor of the mitochondrial respiratory chain exerts synergistic anti‐tumour effects when combined with alkylating agents

British Journal of Pharmacology, EarlyView.
Background and Purpose Cancer cells exhibit the Warburg effect, but oxidative phosphorylation (OXPHOS) is also important for cancer cell proliferation. Metabolic reprogramming from glycolysis to OXPHOS is one mechanism of resistance to anti‐tumour drugs.
Emiri Omori Takaki, Yuya Hidoh, Yutaka Obuchi, Yoko Nagai, Shingo Nishikori, Yuki Kuniyoshi, Yasuhiro Sawai, Naoto Ohi   +7 more
wiley   +1 more source

Response to carboplatin +/− topotecan-containing ophthalmic artery chemosurgery (OAC).

, 2013
Representative case. Left: Reese-Ellsworth Group VB (IC D) left eye prior to treatment Right: Same eye following three OAC cycles consisting of carboplatin and topotecan. Note dramatic response of tumors following carboplatin/topotecan therapy.
Brian P. Marr (307426), David H. Abramson (307429), Jasmine H. Francis (307427), Scott E. Brodie (307428), Gowtham Jonna (448809), Y. Pierre Gobin (307424), Ira J. Dunkel (307425)   +6 more
core   +1 more source